Alloy Therapeutics was selected to join the World Economic Forum’s Unicorns Community, an invitation-only group of high-growth private companies valued at more than $1 billion. Alloy will contribute its experience with AI-powered biotechnology infrastructure and its Product Development Organization model, which supports drug discovery and development without maintaining its own therapeutic pipeline. The company plans to work with leaders across business, government, academia, and civil society on improving medicine development, global health security, and access to biotechnology capabilities.
